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ABSTRACT  
Dendritic cells (DCs) of the skin play an important role in skin-mediated immunity 
capable of promoting potent immune responses. We availed of polymeric dissolving 
microneedle (MN) arrays laden with nano-encapsulated antigen to specifically target 
skin DC networks. This modality of immunization represents an economic, efficient 
and potent means of antigen delivery directly to skin DCs, which are inefficiently 
targeted by more conventional immunization routes. Following MN immunization, 
Langerhans cells (LCs) constituted the major skin DC subset capable of cross-
priming antigen-specific CD8+ T cells ex-vivo. While all DC subsets were equally 
efficient in priming CD4+ T cells, LCs were largely responsible for orchestrating the 
differentiation of CD4+ IFN-  and IL-17 producing effectors. Importantly, depletion of 
LCs prior to immunization had a profound effect on CD8+ CTL responses in vivo, and 
vaccinated animals displayed reduced protective anti-tumour and viral immunity.  
Interestingly, this cross-priming bias was lost following MN immunization with soluble 
antigen, suggesting that processing and cross-presentation of nano-particulate 
antigen is favoured by LCs.  Therefore, these studies highlight the importance of LCs 
in skin immunization strategies and that targeting of nano-particulate immunogens 
through dissolvable polymeric MNs potentially provides a promising technological 
platform for improved vaccination strategies. 
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INTRODUCTION  
Elucidation of the mechanisms that underpin the functional specialization of distinct 
DC populations is important for the development of improved immunotherapies and 
the generation of DC-targeted vaccines, particularly in the skin, which represents an 
attractive site for vaccine delivery (Romani et al., 2010). In normal epidermis, 
langerin (CD207)-expressing Langerhans cells (LCs) constitute the only population 
of professional antigen-presenting cells, while the dermis harbours three distinct 
CD207+ DC subsets: migratory LCs, CD207+CD103+ and CD207+CD103− dermal 
DCs (dDCs), in addition to two CD207− dDC subsets, characterized by differential 
expression of CD11b (Henri et al., 2010).  
Numerous studies have highlighted significant in vivo functional heterogeneity 
among skin DC populations. CD207+ dDCs appear to be required for protective 
immunity in a number of infection and vaccination models, while the precise 
contribution of LCs in promoting immune responses in vivo remains controversial. 
Several studies have questioned whether LCs are required for the generation of 
protective antigen-specific immune responses in different mouse models (Kautz-Neu 
et al., 2011; Ritter at al., 2004; Zhao et al., 2003), while studies permitting the 
conditional or constitutive ablation of CD207+ DCs suggest that LCs instigate 
antigen-specific unresponsiveness or tolerance under homeostatic conditions 
(Schrwarz et al., 2010; Henri et al., 2010; Idoyaga et al., 2013). Another unresolved 
question is whether LCs are capable of efficient cross-priming antigen in vivo 
(Romani et al., 2012), with numerous models attributing this role primarily to CD207+ 
dDCs and lymph node (LN) resident CD8+ DCs (Igyarto and Kaplan, 2013). LCs 
have been shown to stimulate type 2 T-helper (Th) cell responses (Nagao et al., 
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2009; Stoecklinger et al., 2011; Hauser et al., 1989), however, LCs have been 
shown to also evoke Th1 cell responses or activate Th17 cells (Duraisingham et al., 
2009; Mathers et al., 2009; Igyarto et al., 2011).  
In this study, we entrapped the model antigen, ovalbumin (OVA), into Poly-D-L- 
lactide-co-glycolide (PLGA) nanoparticles (NPs), as these particles were previously 
shown to have strong immune-modulatory properties and activate DCs to induce 
efficient T-cell immune responses (Gutierro et al., 2002; Jaganathan et al., 2006). 
Previous studies have demonstrated the capacity of model protein antigens, 
inactivated or subunit vaccines to prime adaptive immunity when delivered via MN 
arrays (Sullivan et al., 2010; Kim et al., 2012). To this end, we employed 
biodegradable polymeric dissolvable MNs to specifically target NP-encapsulated 
antigen to DCs within the different skin compartments to enhance their activation and 
promote adaptive immunity.  Recently, we demonstrated that MN-mediated delivery 
of nano-encapsulated antigen efficiently targeted skin DCs, which in turn induced 
efficient T cell responses (Zaric et al., 2013). However, the contribution of individual 
skin DC subsets in the induction of immune responses using our vaccination strategy 
was not examined in detail. Utilising skin DC ablation models, we demonstrate that 
following MN-mediated NP-immunization, LCs are central in cross-priming antigen in 
vivo and inducing Th1 and Th17 immune responses by antigen-specific CD4+ T 
cells. Importantly, we highlight the prerequisite for LCs to generate both antigen-
specific anti-tumour and anti-viral immune responses following antigen-NPs MN 
immunization.  
RESULTS 
LCs are the major population capable of cross-priming CD8+ T cells  
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To determine the contribution of specific DC subsets following intradermal 
immunization, dissolvable MNs containing OVA encapsulated nanoparticles (OVA-
NPs) were applied to LangeGFP mouse ears, and DC subsets from pooled auricular 
LNs were purified by FACS 24h and 72h post-immunization. Skin-derived DCs 
(CD11c+MHCIIhighCD8-) were sorted into distinct DC subsets on the basis of eGFP, 
CD103 and Ep-CAM expression (Fig. S1). Following co-culture of purified skin DCs 
with CFSE-labelled OVA-specific OT-I CD8+ or OT-II CD4+ T cells, we found that 
LCs constituted the major subset able to cross-present OVA-NPs, although a low 
degree of antigen presentation to CD8+ OT-I T cells was mediated by other dDC 
subsets (Fig. 1a-b). In contrast, all skin DC subsets were equally able to efficiently 
activate and induce CD4+ OT-II cell proliferation in vitro (Fig. 1c-d). Due to their 
observed slower migration to the draining LNs (Kissenpfennig et al., 2005), LCs-
induced OT-I and OT-II T cell proliferation peaked at 72h post MN vaccination. 
Importantly, delivery of TRITC NPs via MN application demonstrated that NPs were 
equally taken up by all skin DC subsets in vivo (Fig. S2). Therefore, LCs are the 
predominant skin DC subset that contribute to cross-priming of naïve antigen-
specific CD8+T cells following immunization with dissolvable MNs laden with antigen-
encapsulated NPs. However, no observed bias by the specific skin DC subsets could 
be discerned for antigen presentation and/or activation of CD4+ T-cells. 
 
LCs are necessary for optimal cross-presentation in vivo  
To substantiate our findings with ex-vivo skin DCs in an in vivo system, we employed 
our LanghDTR model and depleted CD207+ DCs prior to immunization (Kissenpfennig 
et al., 2005). To deplete LCs only, LanghDTR mice were treated i.p. with a single dose 
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of diphtheria toxin (DT) 7 days prior to MN immunization, or a supplementary DT 
dose was given one day prior to immunization to deplete both LCs and CD207+ dDC, 
consistent with previously published studies (Fig. S3) (Poulin et al., 2007; Bursch et 
al., 2007; Ginhoux et al., 2007). One day prior to blank NP (b-NP) or OVA-NP 
immunization, DT untreated or treated LanghDTR mice were adoptively transferred 
with CFSE-labelled CD8+ T cells purified from CD45.1 congenic OT-I mice. 
Expansion of donor CD8+ cells in auricular LNs was analysed 7 days post MN 
immunization. As expected, efficient expansion of antigen-specific CD45.1+CD8+ T 
cells was detected following immunization with OVA-NPs compared to mice 
immunized with b-NPs. In contrast, expansion of OVA-specific CD8+ T cells was 
significantly reduced in LanghDTR mice receiving either DT dosing regimes (Fig. 2a). 
Interestingly, all skin DC subsets had the capacity to induce efficient IFN-  
production among proliferating OT-I cells, notwithstanding that absolute numbers of 
IFN- +OT-I T cells were significantly reduced in the absence of LCs  (Fig. 2b).  
These observations were substantiated in a genuine in vivo model by examining the 
expansion of endogenous OVA-specific CD8+ T cells following MN immunization with 
b-NPs or OVA-NPs. Utilising the same immunization and depletion protocol 
described above, isolated auricular LN cells were stained with OVA257–264/H-2K
b 
pentamers specific for the SIINFEKL epitope of OVA protein two weeks post-
immunization. MN immunization with OVA-NPs resulted in increased percentages 
and total numbers of OVA-specific CD8+ T cells in DT-untreated mice compared to 
mice that had received one or two doses of DT prior to immunization (Fig. 2c), 
reaffirming the requirement for LCs for optimal cross-presentation of nano-
encapsulated antigen following MN intradermal immunization. 
© 2014 The Society for Investigative Dermatology
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LCs promote Th1 and Th17 CD4+ T cell differentiation 
To examine T helper immune responses by different skin-derived DC subsets, we 
adoptively transferred CD45.1+CD4+ OT-II T cells into LanghDTR mice prior to DT 
treatment and MN immunization. No difference in total numbers of donor OT-II cells 
was observed between mice with LCs, and mice lacking LCs only, or both LCs and 
CD207+ dDCs (Fig. 3a-b), confirming that both CD207+ and CD207- dDCs were 
equally capable of presenting OVA-NPs and activating CD4+ T helper cells. The 
cytokine profile of expanded CD45.1+OT-II T cells revealed that the polarisation of 
IFN-  and IL-17A-producing cells necessitated the presence of LCs (Fig. 3c-d), while 
only a few OT-II cells polarized towards IL-4-producing Th2 cells. Interestingly, in the 
absence of LCs, the number of donor OT-II cells producing IL-4 was significantly 
elevated. Of note, we did not observe any notable difference in the induction of 
Foxp3-producing OT-II T cells in our model. Therefore, the absence of LCs has a 
profound effect on the development of Th1 and Th17 cells following MN-mediated 
delivery of nano-particulate antigen. 
 
LCs are necessary for efficient anti-tumour responses following microneedle 
immunization 
We further examined the contribution of LCs in antigen-specific anti-tumour immune 
responses. Utilising the same depletion and immunization strategy as in previous 
experiments, LanghDTR mice were challenged 3 weeks post MN-vaccination with 
B16.OVA tumour cells, and tumour growth was monitored thereafter. As expected, 
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DT-untreated LanghDTR mice immunized with OVA-NPs were protected against 
tumour challenge, while all mice immunized with b-NPs exhibited expected tumour 
growth. In OVA-NPs immunized mice depleted of LCs only, or both LCs and CD207+ 
dDCs, tumours grew at a reduced rate and mice survived longer compared to b-NPs 
immunized mice (Fig. 4a-b), suggesting that all skin DCs contribute to anti-tumour 
immunity following MN-mediated intradermal immunization. However, mice with LCs 
present developed smaller tumours and survived significantly longer than DT-treated 
animals (Fig. 4a-b), highlighting the importance of LCs for optimal anti-tumour 
immunity in this model.  Furthermore, staining of tumour cell suspensions with 
OVA257–264/H-2K
b pentamers identified a clear population of OVA-specific tumour-
infiltrating CD8+ T cells in DT-untreated mice, which was found to be 3-5 fold reduced 
in mice lacking LCs or all CD207+ skin DCs at the time of OVA-NPs immunization 
(Fig. 4c). Similarly, the percentages of tumour-infiltrating total CD8+ T cells were 
increased in DT-untreated mice compared to mice that had received one or two 
doses of DT prior to immunization (Fig. S4). 
To determine the contribution of skin DC subsets in evoking therapeutic anti-tumour 
immunity, DT treated and untreated LanghDTR mice were first injected into the flank 
with B16.OVA tumour cells, and on days 4 and 9 following tumour inoculation they 
were immunized with MNs (Fig. S5). Only tumours from OVA-NPs immunized DT-
untreated animals were significantly affected.  These tumours were notably smaller 
compared to tumours from b-NPs immunized mice 15 days post-tumour inoculation, 
suggesting that the presence of all skin DC subsets in the skin at the time of 
immunization is necessary for robust anti-tumour activity in a therapeutic setting 
(Fig. 4d). Mice survival determined by tumour volume end-point between different 
experimental groups found that irrespective of the presence of LCs, treatments with 
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OVA-NPs MNs prolonged overall survival of mice compared to mice treated with b-
NPs MNs. However, survival was further improved if LCs were present in the skin at 
the time of OVA-NPs MN immunization (Fig. 4e). 
 
LCs are required for effective anti-viral responses following microneedle 
immunization 
To test the capacity of different skin-derived DC subsets to promote protective viral 
immunity following MN-mediated vaccination in a murine para-influenza virus model, 
we utilized a recombinant Sendai virus expressing an ovalbumin/red fluorescent 
fusion protein (SeVOVATdT) (Zaric et al., 2013). LanghDTR mice were either untreated 
or treated with DT, immunized with b-NPs or OVA-NPs, and three weeks later 
intranasally challenged with SeVOVATdT.  All b-NPs immunized animals did not survive 
beyond 6 days post-challenge (Fig. 5a). When depleted of LCs, OVA-NPs 
immunized mice presented with significantly reduced survival compared to DT-
untreated controls that all survived the challenge. Analysis of whole lung cell 
suspensions revealed significantly increased percentages of SeVOVATdT positive cells 
in b-NPs immunized mice compared to untreated OVA-NPs immunized animals. 
Furthermore, there was a 3-5 fold increase in percentages of SeVOVATdT positive cells 
in mice lacking LCs, or both LCs and CD207+ dDCs compared to mice with their full 
complement of skin DCs (Fig. 5b-c). Lung viral titre measurements confirmed 
significantly higher viral titres in DT-treated OVA-NPs immunized mice compared to 
DT-untreated mice, where viral titres were below detection levels (Fig. 5d).  
Analysis of lung cell suspensions 6 days post-challenge revealed that OVA-specific 
CD8+ T cells could consistently be detected in the lungs of OVA-NPs immunized 
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mice (Fig. 5e), while this population was 2-3 fold reduced when LCs or all CD207+-
expressing skin DCs were depleted at the time of MN immunization. We did not 
observe any significant differences in the ability of LCs, or CD207+ and CD207- dDC 
subsets to activate IFN-  and/or Granzyme B expressing CD8+ T cells, as the 
proportion of IFN- + and Granzyme B+ OVA-specific T cells remained similar 
between the different DT treatment groups (Fig. 5f). Collectively, these results 
demonstrate that the presence of LCs in the skin at the time of immunization with 
MNs laden with antigen- NPs is essential for promoting the activation and expansion 
of antigen-specific CD8+ T cells contributing to the complete protection against 
pulmonary viral challenge. 
 
Effective LCs cross-presentation is dependent on nano-encapsulation of 
antigen  
Although our results suggest that LCs represented the predominant DC subset 
capable of cross-priming nano-encapsulated antigen following MN delivery, it was 
unclear whether preferential activation of antigen-specific CD8+ T cells by LCs 
occurred as a consequence of antigen nano-encapsulation or MN-mediated antigen 
delivery. Therefore, we directly compared the ability of different skin-derived DC 
subsets to cross-present antigen delivered by MNs, as either a nano-particulate or a 
non-nano-particulate formulation. MNs containing either OVA-NPs or the comparable 
amount of OVA were applied to mouse ears, and DC subsets from auricular LNs 
were purified by FACS 72h post-immunization as previously described. Following co-
culture of DC subsets with CFSE-labelled OT-I cells, we confirmed that nano-
particulate antigen was again predominantly cross-presented by LCs. In contrast, 
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MN delivery of soluble OVA demonstrated that CD207+CD103+ dDCs were the major 
population responsible for antigen cross-presentation (Fig. 6a). All other skin-derived 
DC subsets, including LCs, can to some extent, cross-present soluble antigen, 
however, the degree of T cell activation by these subsets was significantly reduced 
in comparison to CD207+CD103+ dDCs (Fig. 6b). Importantly, these experiments 
suggest that the physical nature of the immunogen could impact the functional 
specialisation of skin DCs following intradermal immunization.  CD207+CD103+ 
dDCs were found to have a superior ability to cross-prime soluble antigen, while 
cross-presentation of nano-encapsulated antigen was strongly favoured by LCs. 
 
DISCUSSION 
On-going research in skin DC immunobiology, together with development of new 
technologies for manipulating DCs, highlight their promising potential in the 
prevention and treatment of various infectious diseases and cancer (Romani et al., 
2010). However, skin DCs populations are heterogeneous, composed of 
phenotypically and functionally diverse subsets and ensuing immune responses may 
be influenced by the subset of DC involved. Several studies designed to test LC-
mediated cross-presentation in vitro or ex vivo have confirmed their ability to 
efficiently present exogenously acquired antigen to antigen-specific CD8+ T cells 
(Klechevsky et al., 2010, Stoitzner et al., 2006). In line with Stoitzner et al., we show 
here that LCs are also able to efficiently cross present nano-encapsulated antigen to 
OT-I T cells ex vivo following MN-mediated OVA-NPs immunization.  
Extensive data to demonstrate LC cross-presentation in vivo has been limited 
(Igyarto and Kaplan, 2013). To date, cross-presentation of cutaneous antigen has 
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been shown to be dependent on CD207+ CD103+ dDCs (Stoecklinger et al., 2011, 
Bobr et al., 2010), whilst we observed only modest antigen cross-priming by dDCs 
following NPs-MN immunization. In addition, we cannot completely exclude that  
monocyte-derived infiltrating inflammatory DCs (Cheong et al., 2010) played an 
additional role in cross-priming. However, they have been shown to be poorly 
represented in the skin DC migratory fraction of lymph nodes, and had reduced 
capacity for naïve T cell activation in vivo (Tamoutounour et al., 2013). In contrast to 
nano-encapsulated antigen, our data suggests that delivery of soluble antigen was 
most efficiently presented by CD207+ CD103+ dDCs rather than LCs.  Indeed, the 
ability of CD207+CD103+ dDCs to cross present skin-borne antigens to CD8+ T cells 
have been confirmed in several models, such as keratinocyte-restricted expression 
of OVA and infection models of Leishmaniasis, Candida albicans, HSV and Vaccinia 
virus (Henri et al., 2010, Brewig et al., 2009, Igyarto et al., 2011, Bedoui et al., 2009, 
Seneschal et al., 2014). 
The specific downstream intracellular mechanisms following PGLA-NP uptake, 
antigen processing and presentation by DCs and their activation in our vaccination 
model remains poorly understood. PLGA NPs have been shown to specifically 
activate the NLRP3 inflammasome (Yang et al., 2013, Sharp et al., 2009). 
Microneedle-mediated PLGA-NPs vaccination likely activates DC inflammasome 
signaling pathways and this could bias the cross-priming capability of LCs. 
Furthermore, a possible role of Birbeck’s granules, a unique organelle of LCs, in 
controlling intracellular fate of particulate antigens cannot be dismissed and further 
investigation into PLGA-NP LC compartmentalization following uptake and induced 
activation of LCs is warranted. 
© 2014 The Society for Investigative Dermatology
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A recent study, utilising Na-CMC/sucrose dissolvable MN arrays loaded with live 
recombinant adenovirus vector or Texas Red-Dextran demonstrated that CD8+ T cell 
immune responses to adeno-viral vectors or uptake of Texas Red-Dextran was 
largely attributed to the CD11b+CD207- dDC subset (Bachy et al., 2013).  Uptake of 
particulate antigens by DCs is dependent on several antigen-associated properties, 
such as size, shape, surface charge, hydrophobicity/hydrophilicity, as well as 
receptor interactions. Indeed, without specific recognition, PLGA-NPs are naturally 
targeted to DCs through phagocytosis, while adenovirus viral uptake has been 
shown to be receptor mediated through clathrin-mediated endocytosis and protein 
kinase C dependent macro-pinocytosis (Hamdy et al., 2011; Meier and Greber, 
2003).  Likewise, subsequent activation of innate signalling pathways following viral 
or PLGA NPs internalisation may differ. Interestingly, a recent study demonstrated 
that following plasmid DNA intradermal vaccination, CD8+ T cell cross-priming was 
largely instigated by infiltrating, second generation antigen-expressing LCs 
(Elnekave et al., 2014). Therefore, the perceived defined functional allocations 
among distinct skin DC subsets may not necessarily exist, but rather the underlying 
mechanisms that govern antigen processing, presentation and activation of DCs may 
influence their subsequent functional properties and the net immune response.  
MN delivery of antigen-NPs to skin DCs led to efficient priming of antigen-specific 
CD4+ T cells, irrespective of the presence of LCs. However, LCs were primarily 
required for Th1 and Th17 development. Similarly, it has been shown that direct 
presentation of C. albicans-derived antigen by LCs was necessary for the generation 
of antigen-specific Th17 effectors (Igyarto et al., 2011). Contrary, Fujita and co-
workers showed that LCs induced IL-22 producing CD4+ T cells, that at the same 
time, lacked the expression of IL-17 and IFN-  (Fujita et al., 2009).  Therefore, the 
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importance of LCs in maintaining mucosal homeostasis, and for Th17 effector 
responses in our immunization modality would require further confirmation in an 
appropriate pathogenic model. 
Finally, we demonstrate that LCs are necessary for the induction of protective 
antigen-specific anti-viral and anti-tumour immunity. The absence of LCs had a 
dramatic effect on the ability of Sendai infected animals to efficiently clear pulmonary 
viral infection.  This is supported by the observation that selective depletion of LCs in 
vivo at the time of MN vaccination was sufficient to significantly diminish the 
expansion of antigen-specific infiltrating CD8+ T cells, confirming that dDCs had a 
secondary contributory role in cross-priming nano-encapsulated antigen. However, 
dDCs subsets still mediated some delay in tumour growth and prolonged mice 
survival. In mice immunised with OVA-NPs and depleted of LCs, or both LCs and 
CD207+ dDCs, tumours grew at a significantly decreased rate and mice survived 
longer compared to b-NPs immunised mice suggesting that dDCs were in part 
necessary for effective anti-tumour immunity. Indeed, it has recently been shown that 
CD207-CD11b- dDCs may be an important contributor to the cutaneous immune 
environment (Mollah et al., 2014). Moreover, depletion of both LCs and 
CD207+dDCs showed an appreciable trend in increased tumour volumes and inferior 
survival in comparison to mice lacking only LCs, indicating that CD207+ dDCs may 
beneficially contribute to anti-tumour immunity. Therefore, whether LCs alone are 
sufficient to induce this anti-tumour and anti-viral response or synergy with other DC 
subsets is required remains to be determined.   
Importantly, the fact that tumour and viral challenges were performed 3 weeks post-
immunization indicates that LCs were also involved in the induction of memory 
response. Indeed, we have previously confirmed that OVA-NPs MN immunization 
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induced antigen specific memory response in mice challenged with tumour cells 3 
weeks post vaccination (Zaric et al., 2013). However, more long-term challenge 
studies are required to confirm this observation. 
Despite changing paradigms, LCs remain an essential cell in the immune system of 
the skin, at least in the context of antigen-NPs delivery through MNs. Emerging 
nano-technological advances in drug delivery coupled with self-disabling, 
biodegradable, dissolving MN arrays offers an exciting prospect for delivery of 
antigens to easily accessible skin DC populations to improve vaccine efficacy.  
Therefore, these results provide a strong rationale for more in-depth exploration of 
therapies based on MN-mediated antigen-NP targeting of LCs for the treatment of 
infectious diseases and tumours.  
 
MATERIALS AND METHODS 
 
Full details of methods are described in SI Materials and Methods. 
Fabrication of NPs-Loaded MNs  
MNs prepared from aqueous blends of 20% w/w PMVE/MA were fabricated using 
laser-engineered silicone micro-mould templates (Donnelly et al., 2011). MN arrays 
(19×19 array, 600 μm height) containing PLGA NPs were prepared as previously 
described (Zaric et al., 2013).  
Mice 
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Transgenic mice, including LangeGFP reporter mice, LanghDTR mice  (Kissenpfennig et 
al., 2005), OT-I and OT-II mice (The Jackson Lab, USA) (Hogquist et al., 1994; 
Barnden et al., 1998) on a congenic CD45.1 C57BL/6 background were housed 
under specific pathogen-free conditions. All mice employed for experiments were 
between 6 to 10 weeks old, age and sex matched and were sanctioned in 
accordance with the UK Home Office and approved by Queen’s University Belfast 
Animal Welfare and Ethical Review Board. 
MN immunization 
MNs containing 10 μg OVA encapsulated NPs or b-NPs, or soluble OVA were 
applied to the dorsal side of both ears. The MNs were held in place for at least 5 min 
and then removed. 
Depletion of LCs or CD207+ dDCs 
For systemic in vivo depletion of CD207+ DCs, LanghDTR mice were injected i.p. with 
1μg Diphtheria Toxin (DT) (Quadratec Diagnostics Ltd, UK) using the specified 
timing of application.  
Reagents for Flow Cytometry 
Surface marker expression was assessed by flow cytometry using fluorochrome-
conjugated antibodies (BD Biosciences and eBioscience, UK) and PE-labelled 
Kb/SIINFEKL pentamers were purchased from ProImmune, UK. 
In vivo proliferation assays 
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Mice were injected i.v. with 106 CFSE-labelled OT-I or OT-II T cells, 24 hours prior to 
MN immunization. Mice were sacrificed 7 days following MN application, and 
auricular lymph nodes were harvested for FACS analysis.  
Ex-vivo proliferation assay 
DCs sorted from the auricular LNs 24h or 72h post-MN immunization were co-
cultured in triplicates with CFSE-labelled OVA-specific OT-I or OT-II T cells for 60h in 
a 1:10 ratio, and proliferation of T cells was measured by the decrease of CFSE 
fluorescence intensity. 
Tumour challenge 
Three weeks following MN immunization, mice were injected s.c. into the flank with 
105 B16.OVA tumour cells (Brown et al., 2001; kindly provided by P Stoitzner, 
Innsbruck). Tumour size was assessed by measuring the short and long tumour 
diameters using digital callipers. Measurements were stopped when tumour diameter 
reached maximum allowed dimension of 20 mm and mice had to be euthanized, 
according to UK Home Office guidelines and Queens University Belfast ethical 
review committee guidelines.  
Challenge of mice with recombinant Sendai virus-OVA-TdT (SeVOVA-TdT) 
Experimental groups of mice were challenged 3 weeks after MN immunization by 
intranasal instillation of 2x106 pfu SeVOVA-TdT (Zaric et al., 2013) in 30 µl of PBS and 
monitored for up to 7 days.  
Statistical analysis 
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Bars in figures show the mean ± SEM. All numerical data were analyzed for significal 
differences between groups by analyses of variance (ANOVA) with Prism software 
5.0 (GraphPad Software, Inc.) Probability values are expressed as the following: ∗∗∗, 
p < 0.001; ∗∗, p < 0.01; and ∗, p < 0.05. 
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Figure Legends 
Figure 1: All skin-derived DC subsets present antigen to CD4+ T cells, but LCs 
are the major population capable of cross-priming CD8+ T cells ex-vivo. Mice 
(n=20) were immunized through MNs with OVA-NPs, and following 24h or 72h 
defined subsets of DCs from auricular LNs were purified by FACS. 5x104 OVA-
specific CD8+ or CD4+ T cells were co-cultured in triplicates with 5x103 DCs of each 
subset for 60h. a) Representative histograms of CFSE dilutions of OT-I cell 
proliferation. b) Bars graphs representing the percentage of proliferating OT-I T cells. 
c) Representative histograms of CFSE dilutions of OT-II cell proliferation. d) Bars 
graphs representing the percentage of proliferating OT-II T cells. Data have been 
pooled from two separate experiments.  
Figure 2: LCs are the major skin DC subset capable of antigen cross-
presentation in vivo LanghDTR mice that were either untreated (DT-) or treated with 
DT once (DT+) or twice  (DT++), received i.v. 106 CFSE-labelled, CD45.1 OT-I cells. 
Mice were immunized with b-NPs or OVA-NPs the following day and skin-draining 
LNs were harvested 7 days later. a) Percentages and total numbers of CD45.1+OT-I 
cells recovered within each experimental group are shown. b) CFSE and expression 
of IFN-  among CD8+CD45.1+ cells (left panel) and total numbers of IFN-  producing 
OT-I cells within each group are shown (right panel). c) Percentages and total 
numbers of endogenous OVA257–264/H2K
b+CD8+ T cells detected in the auricular LNs 
among different experimental groups are shown. All flow cytometry dot plots 
represent an individual mouse from each experimental group obtained in one out of 
three separate experiments. 
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 Figure 3: LCs promote Th1 and Th17 CD4+ T cell differentiation. DT-untreated 
or treated LanghDTR mice received i.v. 106 CD45.1 OT-II cells. Mice were immunized 
with b-NPs or OVA-NPs the following day and skin-draining LNs were harvested 7 
days later. a) Percentages and total numbers of CD45.1+CD4+T cells recovered 
within each experimental group  are shown. c) Total LN cells were re-stimulated with 
PMA-Ionomycin prior to intracellular staining. The expression of IFN-  and IL-4 
among CD4+CD45.1+ gated cells is shown. c) The same as in b), but the expression 
of IL-17 and Foxp3 among different experimental groups is shown. d) Total numbers 
(mean ± SEM, n=6/group) of IL-4, IFN- , IL-17, IL-10 or Foxp3 expressing OT-II cells 
within each group. 
Figure 4: LCs are necessary for efficient anti-tumour responses. LanghDTR mice 
were DT-treated or untreated and immunized with b-NPs or OVA-NPs MNs. Three 
weeks later, mice were inoculated s.c. with B16.OVA melanoma cells. a) Tumour 
volume measurements (±SEM, n=9/group) over 18 days among experimental 
groups. b) As in a, but percentages of survival among different groups are shown. c) 
Percentages of OVA-specific, among tumour infiltrating CD8+ T cells, between 
experimental groups are shown. d) LanghDTR mice, DT-treated or untreated, were 
injected s.c. with 105 B16.OVA cells, and 4 and 9 days later, immunized with b-NPs 
or OVA-NPs. Tumour volumes (±SEM) among different treatment groups over 15 
days post-inoculation are shown. e) As in d, but percentages of survival among 
treatment groups (n=9/group) are shown.  
Figure 5: LCs are required for effective anti-viral immunity a) LanghDTR mice, 
either DT-untreated or treated, were immunized with b-NPs or OVA-NPs MNs. Mice 
were challenged i.n. with SeVOVATdT 3 weeks later. Survival among experimental 
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groups following SeVOVATdT challenge (n=8-10/group) is shown. b) Representative 
dot-plots indicating percentages of SeVOVATdT positive cells in total lung cell 
suspensions between groups 6 days post-infection. c) Bars indicating percentage of 
SeVOVATdT positive cells in total lung cell suspensions between groups (n=10/group). 
d) Viral titres in lung homogenates between groups at 6 days post-infection. e) 
Percentages of OVA-specific CD8+T cells infiltrating the lungs between immunization 
groups. f) IFN-  and/or Granzyme B production following PMA/Ionomycin re-
stimulation of OVA-specific CD8+T cells infiltrating the lungs, as analysed 6 days 
post SeVOVATdT challenge. 
Figure 6: CD207+CD103+ dDCs preferentially cross-present soluble antigen 
delivered following microneedle immunization. Mice (n=20/group) were 
immunized through MNs with OVA-NPs or soluble OVA, and following 72h defined 
subsets of DCs from auricular LNs of both immunization groups were purified by 
FACS. 3-5x104 OVA-specific CD8+ T cells were co-cultured in triplicates with 3-5x103 
DCs of each subset for 60h. a) Representative histograms of CFSE dilutions of OT-I 
cell proliferation among both immunization groups are shown. b) Bars graphs 
representing the percentage of proliferating OT-I T cells. Data have been pooled 
from two separate experiments and are represented as mean ± SEM.  
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